Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race 2022
2022 Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNAFrontiers in Oncology.  12. 2022
2022 Bladder Cancer, Version 2.2022 Featured Updates to the NCCN GuidelinesJournal of the National Comprehensive Cancer Network : JNCCN.  20:866-878. 2022
2022 Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer 2022
2022 Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network : JNCCN.  20:71-90. 2022
2022 Use of Single-Item Self-Rated Health Measure to Identify Frailty and Geriatric Assessment-Identified Impairments Among Older Adults with Cancer 2022
2021 Association between chronologic age and geriatric assessment⇓identified impairments: Findings from the CARE registryJournal of the National Comprehensive Cancer Network : JNCCN.  19:922-927. 2021
2020 Obesity diminishes response to PD-1-based immunotherapies in renal cancerJournal for ImmunoTherapy of Cancer.  8. 2020
2020 First-In-Human Phase 1 Clinical Trials – A Single-Center Experience In The Era Of Modern OncotherapeuticsScientific Reports.  10. 2020
2020 Kidney cancer, version 1.2021: Featured updates to the nccn guidelinesJournal of the National Comprehensive Cancer Network : JNCCN.  18:1160-1170. 2020
2020 Patient-reported cognitive complaints in older adults with gastrointestinal malignancies at diagnosis– Results from the Cancer & Aging Resilience Evaluation (CARE) studyJournal of Geriatric Oncology.  11:982-988. 2020
2020 Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE)Journal of Geriatric Oncology.  11:270-273. 2020
2020 Bladder cancer, version 3.2020Journal of the National Comprehensive Cancer Network : JNCCN.  18:329-354. 2020
2019 Investigational MET inhibitors to treat Renal cell carcinomaExpert Opinion on Investigational Drugs.  28:851-860. 2019
2019 Correction to: Immunotherapy Advances in Urothelial Carcinoma (Current Treatment Options in Oncology, (2018), 19, 12, (79), 10.1007/s11864-018-0598-x)Current Treatment Options in Oncology.  20. 2019
2019 Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancerCancer.  125:1459-1469. 2019
2019 Featured updates to the NCCN guidelinesJournal of the National Comprehensive Cancer Network : JNCCN.  17:1278-1285. 2019
2018 Correlation between Dt/V derived from ionic dialysance and blood-driven Kt/V of urea in African-American hemodialysis patients, based on body weight and ultrafiltration volumeClinical Kidney Journal.  11:734-741. 2018
2018 Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell CarcinomaCurrent Treatment Options in Oncology.  19. 2018
2017 Timing of androgen-deprivation therapy in prostate cancer 2017
2017 Treatment approaches of hard-to-treat non-Hodgkin lymphomasExpert Review of Hematology.  10:259-273. 2017
2016 Bronchoscopy can be done safely in patients with thrombocytopeniaTransfusion.  56:344-348. 2016
2016 Circulating biomarkers in bladder cancerBladder cancer.  2:369-379. 2016
2014 Ectopic ACTH and cisplatin toxicity-a diagnostic dilemmaAmerican Journal of Therapeutics.  21:e154-e156. 2014
2013 A rare cause of dysphagia in a HIV patient - esophageal pseudodiverticulosisActa Gastro-Enterologica Belgica.  76:340-341. 2013
2013 Sterile peritonitis because of splenic infarction in a patient on peritoneal dialysis: An unusual presentationAdvances in peritoneal dialysis. Conference on Peritoneal Dialysis.  33:339-340. 2013

Research Overview

  • Dr. Nandagopal’s primary clinic interest is interested in genitourinary (GU) malignancies. His research interests are in developing clinical trials for GU malignancies, and development of correlative and prognostic biomarkers.
  • Investigator On

  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC.
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC
  • Private Grant  awarded by ADURO BIOTECH, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ARCUS BIOSCIENCES INC
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by HOOKIPA BIOTECH
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by QED THERAPEUTICS INC
  • Private Grant  awarded by BLUE EARTH DIAGNONSTICS LTD ^
  • Private Grant  awarded by TAKEDA PHARMACEUTICALS COMPANY LTD
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by ELEVATION ONCOLOGY INC.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by IMMUNOMEDICS, INC.
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by CHECKMATE PHARMACEUTICALS INC
  • Private Grant  awarded by IMMUTEP LTD
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC
  • Private Grant  awarded by CHECKMATE PHARMACEUTICALS INC
  • Private Grant  awarded by I-MAB BIOPHARMA US LIMITED
  • UAB 1984: Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and/or Nivolumab  awarded by CLEVELAND CLINIC FOUNDATION
  • Full Name

  • Lakshminarayanan Nandagopal